High-Throughput Accurate Mass Solution for Drug Discovery

Biocius Life Sciences, Inc and Agilent Technologies, Inc announced the launch of the RF360 High Resolution System for highthroughput screening of in vitro ADME assays. Combining the accurate mass capabilities of Agilent’s time-of-flight (TOF) mass spectrometers and the unprecedented sample processing speed of RapidFire® technology, the instrument revolutionises in vitro ADME analysis by eliminating the method development bottleneck in drug discovery.

This revolutionary approach to in vitro ADME has been demonstrated to reduce analysis time to a fraction of that of conventional methods while requiring a minimal amount of operator input.

RapidFire technology combined with TOF mass spectrometers enables a wide range of ADME assays, including drug-drug interaction, metabolic stability, Caco, PAMPA and others. When performing such assays with the RF360, a priori knowledge of the test compound is not required, as data is acquired in full scan TOF-MS mode. Post acquisition, the relevant data is extracted using RapidFire software, eliminating the time consuming and labor-intensive steps of LC/MS method development and batch analysis.

“Only TOF spectrometry can meet the scan speed and resolution demands required for these high-throughput types of applications,” said Gustavo Salem, Vice President and General Manager of Agilent’s Biological Systems Division. “Partnering with Biocius on the RF360 has provided a solution that is the fastest approach to ADME on the market.”